Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials

Find Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Near You

Additional Effects of Flutter With Conventional Chest Physiotherapy on Peak Expiratory Flow Rate and Chest Expansion in Post CABG Patients With COPD

Status: Recruiting
Location: See location...
Intervention Type: Procedure, Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Flutter therapy is an oscillating positive expiratory pressure (OPEP) technique that combines positive expiratory pressure with airway oscillations to facilitate mobilization and clearance of respiratory secretions. Conventional chest physiotherapy includes deep breathing exercises, incentive spirometry, airway-clearance techniques, splinted coughing and early mobilization to promote lung expansion and secretion clearance. A total of 94 patients aged 40-70 years with mild-to-moderate COPD undergoing elective coronary artery bypass grafting (CABG) will be enrolled in this randomized controlled trial and will be randomly allocated into two groups, with 47 participants in each group. The intervention group will receive conventional chest physiotherapy combined with Flutter therapy, while the control group will receive conventional chest physiotherapy alone. Both groups will receive supervised treatment for 5 consecutive postoperative days, with 3 sessions per day, resulting in 15 treatment sessions. Baseline assessment will be performed on postoperative day 1 before commencement of the intervention, and post-intervention assessment will be conducted on postoperative day 5. The study will compare the effects of Flutter-assisted conventional chest physiotherapy versus conventional chest physiotherapy alone on postoperative peak expiratory flow rate, chest expansion and airway clearance.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 70
Healthy Volunteers: f
View:

• Adults aged 40-70 years undergoing elective CABG

• Pre-existing COPD (mild- moderate), clinically diagnosed COPD

• Early post-operative (24-72 hrs.), extubated and hemodynamically stable

• No mechanical ventilation beyond 24 hrs., stable vitals (HR: 60-100bpm, SBP :110-130mmhg), no vasopressors.

• Follow commands, provide consent and perform assessments.

Locations
Other Locations
Pakistan
Foundation University Islamabad
RECRUITING
Rawalpindi
Contact Information
Primary
Kashaf Nadeem, MS-CPPT
kashafnadeem460@gmail.com
+923349058792
Backup
Syeda Sumaira Batool, MS-CPPT
sumaira.batool@fui.edu.pk
+923328868680
Time Frame
Start Date: 2026-02-11
Estimated Completion Date: 2026-12-20
Participants
Target number of participants: 84
Treatments
Active_comparator: Group A: conventional chest physiotherapy
Participants allocated to Group A (control group) will receive conventional chest physiotherapy during the early postoperative period following CABG. The intervention will comprise deep breathing exercises, incentive spirometry, airway-clearance techniques, splinted coughing and early mobilization. Treatment will be administered under supervision for 5 consecutive postoperative days, with 3 sessions per day, resulting in a total of 15 treatment sessions. The techniques will be performed according to the standardized study protocol and adapted to the participant's postoperative clinical status and tolerance
Experimental: Group B: Flutter therapy
Participants allocated to Group B (intervention group) will receive conventional chest physiotherapy combined with Flutter therapy during the early postoperative period following CABG. Flutter therapy will be administered as an adjunct to conventional chest physiotherapy using an oscillating positive expiratory pressure (OPEP) device to facilitate airway secretion clearance. Treatment will be supervised for 5 consecutive postoperative days, with 3 sessions per day, resulting in a total of 15 sessions. The intervention will be adapted according to the participant's postoperative clinical status and tolerance.
Sponsors
Leads: Foundation University Islamabad

This content was sourced from clinicaltrials.gov